Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G. Monk BJ, et al. Among authors: higgins r. Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049. Ann Oncol. 2017. PMID: 28453702 Free PMC article. Clinical Trial.
Nutrition's checkpoint inhibition: The impact of nutrition on immunotherapy outcomes.
Vaz J, Piver R, Brzezinska B, Suhner J, Sareddy S, Vuppala P, Vernon M, Xu H, Rungruang B, Johnson M, Higgins RV, Ghamande S, Richardson KP, McIndoe R, Purohit S, Mysona D. Vaz J, et al. Among authors: higgins rv. Gynecol Oncol. 2024 Oct;189:129-136. doi: 10.1016/j.ygyno.2024.07.685. Epub 2024 Aug 7. Gynecol Oncol. 2024. PMID: 39116830
Pembrolizumab-induced myasthenia gravis: Two patients' experiences.
Montag L, Piver R, Vidalin A, Johnson M, Rungruang B, Higgins R. Montag L, et al. Among authors: higgins r. Gynecol Oncol Rep. 2024 Jul 4;54:101453. doi: 10.1016/j.gore.2024.101453. eCollection 2024 Aug. Gynecol Oncol Rep. 2024. PMID: 39108615 Free PMC article.
Ovarian recurrence risk assessment using machine learning, clinical information, and serum protein levels to predict survival in high grade ovarian cancer.
Mysona DP, Purohit S, Richardson KP, Suhner J, Brzezinska B, Rungruang B, Hopkins D, Bearden G, Higgins R, Johnson M, Bin Satter K, McIndoe R, Ghamande S. Mysona DP, et al. Among authors: higgins r. Sci Rep. 2023 Nov 27;13(1):20933. doi: 10.1038/s41598-023-47983-z. Sci Rep. 2023. PMID: 38016985 Free PMC article.
High serum levels of inflammatory markers are associated with early recurrence in patients with high-grade serous ovarian cancer after platinum therapy.
Brzezinska B, Mysona DP, Richardson KP, Rungruang B, Hopkins D, Bearden G, Higgins R, Johnson M, Satter KB, McIndoe R, Ghamande S, Purohit S. Brzezinska B, et al. Among authors: higgins r. Gynecol Oncol. 2023 Dec;179:1-8. doi: 10.1016/j.ygyno.2023.10.009. Epub 2023 Oct 19. Gynecol Oncol. 2023. PMID: 37862814
1,704 results